Cerus Corporation clinical trial pipeline

4 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 1 with a minor change only.

1. Notable

   Challenge · Transfusion of INTERCEPT Pathogen Reduced Red Blood…Challenge · Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) · or Without Pre-existing Antibodies to INTERCEPT RBCs

   Primary completion pushed from Oct 1, 2027 to Sep 30, 2030

   Also in this update: Enrollment increased: 10 → 25 participants; Study completion pushed from Jan 1, 2028 to Dec 30, 2030; and 1 more change in the last 30 days

   Cerus Corporation·Phase 2· NCT07152379· Registry history of NCT07152379 on ClinicalTrials.gov (opens the registry)

   Updated Sep 22, 2026

2. Notable

   CRYO-FIRST · INTERCEPT Fibrinogen Complex (IFC) for…CRYO-FIRST · INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage

   Enrolling by invitation only

   Cerus Corporation·Not specified· NCT07218185· Registry history of NCT07218185 on ClinicalTrials.gov (opens the registry)

   Updated Oct 14, 2026

3. Notable

   Recovery and Lifespan Study Using INTERCEPT Red Blood Cells…Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1

   Enrollment increased: 70 → 120 participants

   Also in this update: Primary completion pushed from Jul 30, 2026 to Dec 15, 2026; Study completion pushed from Oct 15, 2026 to Feb 13, 2027

   Cerus Corporation·Phase 2· NCT07015437· Registry history of NCT07015437 on ClinicalTrials.gov (opens the registry)

   Updated Sep 21, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.